Donald Banerji

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

Jadwiga A. Wedzicha, Donald Banerji, Kenneth R. Chapman et al. · New England Journal of Medicine · 2016 · 852 citations · Full text

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

Jadwiga A. Wedzicha, Marc Decramer, Joachim H. Ficker et al. · The Lancet Respiratory Medicine · 2013 · 538 citations

Asthma, Advanced Lung Disease, Parallel-group Study +4

Dual bronchodilation with QVA149<i>versus</i>single bronchodilator therapy: the SHINE study

Eric Bateman, Gary T. Ferguson, Neil Barnes et al. · European Respiratory Journal · 2013 · 377 citations · Full text

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study

Claus Vogelmeier, Eric Bateman, John Pallante et al. · The Lancet Respiratory Medicine · 2012 · 312 citations

Twice-daily Salmeterol–fluticasone, Pulmonary Care, Allergy +8

Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial

Kenneth R. Chapman, John R. Hurst, Stefan Frent et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 256 citations